Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$110.28 USD

110.28
9,182,186

0.00 (0.00%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $113.75 +3.47 (3.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.

Zacks Equity Research

Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study

by Zacks Equity Research

Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.

Mark Vickery headshot

Top Stock Reports for FEMSA, NextEra Energy & Sanofi

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Fomento Economico Mexicano, S.A.B. de C.V. (FMX), NextEra Energy, Inc. (NEE) and Sanofi (SNY).

Zacks Equity Research

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

Zacks Equity Research

Pfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults

by Zacks Equity Research

Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.

Zacks Equity Research

Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use

by Zacks Equity Research

Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.

Zacks Equity Research

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ONEY

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

by Zacks Equity Research

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

Zacks Equity Research

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for CLRG

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Zacks Equity Research

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for ONEY

Zacks Equity Research

Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for CLRG

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

Zacks Equity Research

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

by Zacks Equity Research

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

Zacks Equity Research

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More

by Ahan Chakraborty

Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27.

Zacks Equity Research

Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Andrew Rocco headshot

Big Tech Earnings & Economic Numbers: 3 Ways to Survive the Week Ahead

by Andrew Rocco

Many of the FANG stocks are slated to report earnings this week. Today, we will lay out how investors can best navigate the action packed week ahead.

Zacks Equity Research

Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results.

Zacks Equity Research

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.

Zacks Equity Research

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day.

Zacks Equity Research

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SPYD